NEW YORK (GenomeWeb News) – Metabolon has raised $5.3 million from a Series C funding round, the firm said today.

The Research Triangle Park, NC-based metabolomics services company said that it anticipates raising a total of $11 million in the round. It closed the first $5.3 million last week, and it expects to receive the rest of the funding within the next 60 to 90 days.

Metabolon CEO John Ryals said that the funding will enable the firm to launch its diagnostics business with products for prostate cancer and insulin resistance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.